Silver Book Fact

Growth hormone treatment in patients with fibromyalgia is effective in reducing pain with sustained action over time.

Cuatrecasas, Guileem, C Alegre, J Fernandez-Sola, MJ Gonzalez, F Garcia-Fructuoso, V Poca-Dias, A Nadal, Gabriel Cuatrecasas, F Navarro, A Mera, M Lage, R Peino, F Casanueva, C Linan, G Sesmilo, MJ Coves, JP Izquierdo, I Alvarez, E Granadas, adn M Puig-Domingo. Growth Hormone Treatment for Sustained Pain Reduction and Improvement in Quality of Life in Severe Fibromyalgia. Pain. 2012; 153(7): 1382-9. http://www.ncbi.nlm.nih.gov/pubmed/22465047

Reference

Title
Growth Hormone Treatment for Sustained Pain Reduction and Improvement in Quality of Life in Severe Fibromyalgia
Publication
Pain
Publication Date
2012
Authors
Cuatrecasas, Guileem, C Alegre, J Fernandez-Sola, MJ Gonzalez, F Garcia-Fructuoso, V Poca-Dias, A Nadal, Gabriel Cuatrecasas, F Navarro, A Mera, M Lage, R Peino, F Casanueva, C Linan, G Sesmilo, MJ Coves, JP Izquierdo, I Alvarez, E Granadas, adn M Puig-Domingo
Volume & Issue
Volume 153, Issue 7
Pages
1382-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Topical NSAIDs were found in a meta-analysis to be significantly more effective than placebo in reducing persistent pain from musculoskeletal conditions.  
  • The Mayo Clinic Pain Rehabilitation Center helps people with persistent pain return to an active lifestyle and has found that among patients who finish the program, nearly 84% report greater…  
  • Nerve growth factor (NGF) has been found to be a major mediator of inflammatory and neuropathic pain and provides a new therapeutic target.  
  • A biopsychosocial approach (i.e., one that takes into account physical, emotional, and environmental factors in the assessment and treatment of pain) has been found to improve the pain care of…  
  • A proteasome inhibitor was found to reduce pain and joint destruction in an animal model of osteoarthritis, suggesting that nontoxic proteasome inhibitors could offer a novel pharmacotherapy option.